Skip to main content
Go to the home page of the European Commission (opens in new window)
English English
CORDIS - EU research results
CORDIS

AI-powered Adaptive radiation dosimetry: An innovative solution for safer and precise MRI guided RadioTherapy

Project description

Cancer radiotherapy based on an AI-powered MRI-guided system

Modern cancer radiology treatment is guided by semi-automatic treatment planning systems. A complete radiotherapy treatment plan depends on the information obtained by computed tomography scanning, which involves toxic materials with potential side effects. Recently, a new concept of treatment was developed based on an MRI-guided planning system that provides non-toxic and high-resolution MRI for radiotherapy administration. The EU-funded ART-AI project is developing a state-of-the-art fully AI-automated treatment planning system for an MRI-guided radiotherapy procedure. This platform will apply proprietary algorithms for anatomical simulation for rapid updates of the treatment plan and automatic and precise patient position adjustment inside the linear accelerator. The current phase of the project involves final development of all software modules for the platform and clinical validation.

Objective

Current radiotherapy is fully reliant on semi-automatic treatment planning systems (TPS) that depend on highly toxic CT scans and human clinical expertise for creating a treatment plan. As a result, the procedure is inefficient and inefficacious resulting in poor treatment outcome and severe side effects. In recent years, there has been an emergence of the concept of MRI-guided radiotherapy, wherein non-toxic and high resolution MRI images are used to guide treatment planning. As a result, several key players in the radiotherapy market such as Elekta and ViewRay have introduced MRI embedded linear acclerators to perform MRI imaging during radiotherapy administration. However, as of yet no TPS exists on the market that enables fully automated MRI-guided radiotherapy, in order to provide real-time dose adjustment.

To meet this market gap, TheraPanacea, a young start-up working on cutting edge AI technology, aims to introduce the world's first fully automated TPS for MRI guided radiotherapy - the ART-AI platform. This platform is built using state-of-the-art technology in reinforcement learning and employs proprietary Monte Carlo algorithms to perform anatomical simulation using MRI images to rapidly update the treatment plan on-the-fly. Moreover, the platform employs latest advances in positioning algorithms via a deformable registration framework to ensure automatic and precise patient position adjustment inside the linear accelerator. Thus, the ART-AI platform has the potential to revolutionize radiotherapy and enable it to achieve its full potential.

In this SME-2 project, we will finalize the development steps of the platform, incoporate all the software modules into one suite and perform clinical validation in collaboration with our clinical partners. The end-result of this SME-2 project will be a fully validated software platform ready for commercial launch.

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.

You need to log in or register to use this function

Keywords

Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)

Programme(s)

Multi-annual funding programmes that define the EU’s priorities for research and innovation.

Topic(s)

Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.

Funding Scheme

Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.

SME - SME instrument

See all projects funded under this funding scheme

Call for proposal

Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.

(opens in new window) H2020-EIC-SMEInst-2018-2020

See all projects funded under this call

Coordinator

THERAPANACEA
Net EU contribution

Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.

€ 2 477 708,00
Address
24 RUE DU FAUBOURG SAINT-JACQUES
75014 Paris
France

See on map

SME

The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.

Yes
Region
Ile-de-France Ile-de-France Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Total cost

The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.

€ 3 539 583,75
My booklet 0 0